Maternal serum placental growth hormone and insulinlike growth factor binding proteins 1 and 3 in pregnancies affected by fetal aneuploidy and other abnormalities: implications for prenatal diagnosis of trisomy 21

In the present study, we determined circulating serum levels of human placental growth hormone (hPGH) and insulinlike growth factor binding proteins 1 and 3 (IGFBP-1 and IGFBP-3) using two-site radioimmunoassays during the gestational midtrimester of pregnancies affected by chromosomal disorders with the aim of identifying potential marker substances that might have a significant discriminative and predictive value for prenatal diagnosis of fetal chromosomal aberrations and of organ malformations such as neural-tube defect. Our results show that the maternal serum levels of hPGH were significantly elevated in pregnancies affected by chromosomal anomalies or organ malformations as compared with controls. The distribution of IGFBP-1 concentrations for all experimental groups except trisomy 21 were closely similar to the normal population. IGFBP-3 decreased slightly in pregnancies affected by Down syndrome. These findings suggest that hPGH may be useful as an additional marker in prenatal screening for Down syndrome.

Detection of autoantibodies to nuclear antigens by EIA and IF techniques

The detection of antibodies to certain nuclear components has considerable importance in the diagnosis and management of patients with autoimmune diseases. In this study, antibodies to nuclear antigens in 250 positive and negative patient specimens were detected by immunofluorescence (IF) and enzyme immunoassay (EIA). Specimens were tested by three different EIA assays for autoantibodies to SS-A, SS-B, Scl-70 Sm, RNP, Jo-1, ENA, Histone, ss-DNA and ds-DNA and one IF assay for Antinuclear Antibodies (ANA). The majority of positive specimens were also confirmed positive by Western Blot. Ninety-seven percent of IF-ANA positive specimens assayed positive by EIA-ENA assay and only 6% of ENA negative specimens tested positive in IF-ANA assay indicating that EIA-ENA assay is as reliable as IF-ANA for screening patient specimens. Forty-five percent of EIA Jo-1 positive specimens showed negative IF-ANA results indicating that IF-ANA assay is not a reliable method for detection of antibodies to Jo-1. This may be due to the fact that specimens with low titer and sera which are positive for a limited number of specific nuclear antigen(s) cannot produce visible or clear fluorescence patterns and therefore are reported negative by IF-ANA. Our data shows that both methods are reliable for screening purposes, however EIA has greater specificity over IF because the presence or absence of antibody to a specific antigen can be better assessed. Overall, due to higher reproducibility, low cost, antigen specificity, and the nature of EIA, we recommend microtiter-based EIA assays for detection of antibodies to nuclear antigens.

COVID-19 vaccines breakthrough infection and adverse reactions in medical students: a nationwide survey in Iran

INTRODUCTION

There are different types of COVID-19 vaccines approved worldwide. Since no national studies focus on vaccine-related adverse reactions and breakthrough cases, this study aimed to investigate the rate of adverse events and COVID-19 infection in medical students in Iran.

METHODS

This retrospective cohort study included Iranian medical students who received two doses of COVID-19 vaccines. The medical team gathered the demographic characteristics, comorbidities, type of vaccine, adverse events following vaccination, and history of COVID-19 infection data through a phone interview. The frequency of adverse events and breakthrough infection was stratified by vaccine type (ChAdOx1-S, Gam-COVID-Vac, and BIBP-CorV).

RESULTS

A total of 3,591 medical students enrolled in this study, of which 57.02% were females, with a mean age of 23.31 + 4.87. A PCR-confirmed and suspicious-for-COVID-19 breakthrough infection rate of 4.51 and 7.02% was detected, respectively. There was no significant relation between breakthrough infection and gender, BMI, blood groups, and comorbidities. However, there was a significant difference in breakthrough infection rate among different types of vaccines (p = 0.001) and history of COVID-19 infection (p = 0.001). A total of 16 participants were hospitalized due to COVID-19 infection after vaccination for reasons such as dyspnea, abnormal imaging, or decreased oxygen saturation. No severe infection or death was observed in the studied population.

CONCLUSION

Vaccination prevented severe COVID-19 infection, although a high breakthrough infection rate was evident among Iranian medical students during the Delta variant's peak. Vaccine effectiveness may be fragile during emerging new variants and in high-exposure settings. Moreover, adverse events are rare, and the benefits of vaccination outweigh the side effects. However, many limitations challenged this study, and the results should be cautious.